Actinium Pharmaceuticals: Business Model, SWOT Analysis, and Competitors 2026

Actinium Pharmaceuticals, Inc. stands as a leading company in Healthcare. Generating $90,000 in annual revenue (continuing to scale) and carrying a market capitalization of $36.81 million, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Actinium Pharmaceuticals, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Actinium Pharmaceuticals, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Actinium Pharmaceuticals, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Actinium Pharmaceuticals, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How Actinium Pharmaceuticals, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Actinium Pharmaceuticals, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Actinium Pharmaceuticals, Inc.'s main competitors are and how the company compares on key financial metrics
4. Actinium Pharmaceuticals, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Actinium Pharmaceuticals, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $90,000 annual revenue (TTM)
• Market Cap: $36.81 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 100.0%, operating margin -6324.4%, net margin 0.0%
• Free Cash Flow: $-13.22 million
• Return on Equity: -133.1% — reflects current investment phase
• Employees: 25 worldwide

Who Owns Actinium Pharmaceuticals, Inc.?

Actinium Pharmaceuticals, Inc. is publicly traded on the ASE under the ticker symbol ATNM. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Actinium Pharmaceuticals, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Actinium Pharmaceuticals, Inc. has approximately 0.03 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $1.18 per share as of early 2026.

Actinium Pharmaceuticals, Inc.'s Mission Statement

Actinium Pharmaceuticals, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Actinium Pharmaceuticals, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Actinium Pharmaceuticals, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Actinium Pharmaceuticals, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Actinium Pharmaceuticals, Inc. Make Money?

As of 2026, Actinium Pharmaceuticals, Inc. generates $90,000 in annual revenue, with a 100.0% gross margin and -6324.4% operating margin. Market capitalization stands at $36.81 million. Here is how the company generates its revenue:

Core Focus

Actinium Pharmaceuticals operates primarily in the oncology sector, specializing in the development of innovative therapies that leverage radioactive isotopes for targeted treatment. The company's flagship product, Iomab-B, is designed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and utilizes an alpha-emitting isotope to target cancer cells precisely while sparing healthy tissue.

Revenue Generation

Actinium's business model revolves around several key components:

1. Product Development: The company focuses on developing advanced therapeutics that target specific cancers. This involves significant research and clinical trials, which can be capital intensive but essential for bringing new products to market.

2. Partnerships and Collaborations: To enhance its research capabilities and expedite product development, Actinium engages in partnerships with research institutions and larger pharmaceutical companies. These collaborations often involve co-development agreements or licensing arrangements, which can provide additional revenue streams.

3. Regulatory Approvals: The successful approval of products by regulatory bodies, such as the FDA, is crucial for Actinium's revenue generation. Securing approvals not only allows the company to launch its products but also enhances its market credibility.

4. Market Penetration and Expansion: Actinium aims to expand its market reach by targeting international markets and exploring broader applications for its existing products. This includes diversifying its pipeline to include therapies for other malignancies.

5. Investor Funding: As a growing biopharmaceutical company, Actinium regularly seeks funding through public offerings, private placements, and grants. This influx of capital is vital for ongoing research and operational expenses.

Pipeline Development

Actinium has an extensive pipeline that includes various clinical-stage candidates, which demonstrates its commitment to innovation. The company’s pipeline is focused on:

• Iomab-ACT: A therapy aimed at improving outcomes in patients undergoing hematopoietic stem cell transplants.
• Actinium-225: A promising agent being explored for its potential to target solid tumors.

The advancement of these therapies through clinical trials is crucial for Actinium's long-term growth and sustainability.

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Actinium Pharmaceuticals, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Actinium Pharmaceuticals, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Actinium Pharmaceuticals, Inc. creates, delivers, and captures value.

Key Partners: Actinium Pharmaceuticals, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Actinium Pharmaceuticals, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Actinium Pharmaceuticals, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (25 employees), proprietary technology, and financial resources ($53.39M in cash).

Value Propositions: Actinium Pharmaceuticals, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: Actinium Pharmaceuticals, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Actinium Pharmaceuticals, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Actinium Pharmaceuticals, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Actinium Pharmaceuticals, Inc.'s major costs include cost of goods sold (0.0% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 6424.4% of revenue.

Revenue Streams: Actinium Pharmaceuticals, Inc. generates revenue through its core product and service offerings.

Actinium Pharmaceuticals, Inc. Competitors

Actinium Pharmaceuticals, Inc.'s main competitors include Actinium Pharmaceuticals. The company operates in the Biotechnology segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

Actinium Pharmaceuticals, Inc.'s competitive position in Biotechnology is defined by its $36.81M market capitalization and 100.0% gross margins. Key competitive advantages include brand recognition and operational scale in the Biotechnology market.

Actinium Pharmaceuticals, Inc. SWOT Analysis

A SWOT analysis examines Actinium Pharmaceuticals, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Actinium Pharmaceuticals, Inc.'s gross margin of 100.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -6324.4% demonstrates disciplined cost management even at scale.

Weaknesses

• Competitive Scale Pressure: In the Biotechnology sector, larger competitors with greater economies of scale can exert pricing pressure and outspend Actinium Pharmaceuticals, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: Actinium Pharmaceuticals, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Actinium Pharmaceuticals, Inc.'s products and services.
• Strategic Acquisitions: With $53.39M in cash and strong free cash flow generation, Actinium Pharmaceuticals, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Actinium Pharmaceuticals, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Actinium Pharmaceuticals, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Actinium Pharmaceuticals, Inc. enters 2026 as a significant player in the Biotechnology market, with a strategy focused on sustainable growth and competitive positioning in a rapidly evolving sector.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Actinium Pharmaceuticals, Inc.'s core markets.

For investors and analysts, Actinium Pharmaceuticals, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Actinium Pharmaceuticals, SEC EDGAR – Actinium Pharmaceuticals Filings, and Actinium Pharmaceuticals's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What is Actinium Pharmaceuticals known for?

Actinium Pharmaceuticals, Inc. operates in the Biotechnology segment of the Healthcare sector. For detailed and current information, investors should consult the company's official investor relations page and latest annual report (10-K or equivalent).

2. What are the main products in Actinium's pipeline?

Actinium Pharmaceuticals, Inc. operates in the Biotechnology segment of the Healthcare sector. For detailed and current information, investors should consult the company's official investor relations page and latest annual report (10-K or equivalent).

3. Who are the main competitors of Actinium Pharmaceuticals?

Actinium Pharmaceuticals, Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

4. What are the strengths of Actinium Pharmaceuticals?

Actinium Pharmaceuticals, Inc.'s core strengths include: Actinium Pharmaceuticals, Inc.'s gross margin of 100.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -6324.4% These advantages contribute to the company's durable competitive position in the Biotechnology sector.

5. What challenges does Actinium Pharmaceuticals face?

Actinium Pharmaceuticals, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Actinium Pharmaceuticals, Inc.'s revenue is not fully insulated from macroeconomic cycles, a Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Actinium Pharmaceut Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

6. How is Actinium Pharmaceuticals funded?

Actinium Pharmaceuticals, Inc. operates in the Biotechnology segment of the Healthcare sector. For detailed and current information, investors should consult the company's official investor relations page and latest annual report (10-K or equivalent).